Clinical Physiology and Nuclear Medicine unit, Department of Translational Medicine, Malmö, Lund University, Malmö, Sweden.
Respiratory Medicine and Allergology unit, Department of Clinical Sciences, Lund, Lund University, Lund, Sweden.
PLoS One. 2019 Feb 21;14(2):e0211987. doi: 10.1371/journal.pone.0211987. eCollection 2019.
Matrix metalloproteinases (MMP´s) are known biomarkers of atherosclerosis. MMP´s are also involved in the pathophysiological processes underlying chronic obstructive pulmonary disease (COPD). Cigarette smoking plays an important role in both disease states and is also known to affect the concentration and activity of MMP´s systemically. Unfortunately, the epidemiological data concerning the value of MMP´s as biomarkers of COPD and atherosclerosis with special regards to smoking habits are limited.
450 middle-aged subjects with records of smoking habits and tobacco consumption were examined with comprehensive spirometry, carotid ultrasound examination and biomarker analysis of MMP-1, -3, -7, -10 and -12. Due to missing data 33 subjects were excluded.
The remaining 417 participants were divided into 4 different groups. Group I (n = 157, no plaque and no COPD), group II (n = 136, plaque but no COPD), group III (n = 43, COPD but no plaque) and group IV (n = 81, plaque and COPD). Serum levels of MMP-1,-7,-10-12 were significantly influenced by smoking, and MMP-1, -3, -7 and-12 were elevated in subjects with COPD and carotid plaque. This remained statistically significant for MMP-1 and-12 after adjusting for traditional risk factors.
COPD and concomitant plaque in the carotid artery were associated with elevated levels of MMP-1 and -MMP-12 even when adjusting for risk factors. Further studies are needed to elucidate if these two MMP´s could be useful as biomarkers in a clinical setting. Smoking was associated with increased serum levels of MMP´s (except for MMP-3) and should be taken into account when interpreting serum MMP results.
基质金属蛋白酶（MMPs）是动脉粥样硬化的已知生物标志物。MMPs 也参与慢性阻塞性肺疾病（COPD）的病理生理过程。吸烟在这两种疾病状态中都起着重要作用，并且已知它还会影响 MMP 系统的浓度和活性。不幸的是，关于 MMP 作为 COPD 和动脉粥样硬化生物标志物的流行病学数据，特别是关于吸烟习惯的，是有限的。
对 450 名有吸烟习惯和烟草消费记录的中年受试者进行了全面的肺功能检查、颈动脉超声检查和 MMP-1、-3、-7、-10 和 -12 的生物标志物分析。由于数据缺失，33 名受试者被排除在外。
剩余的 417 名参与者被分为 4 个不同的组。组 I（n = 157，无斑块且无 COPD）、组 II（n = 136，有斑块但无 COPD）、组 III（n = 43，有 COPD 但无斑块）和组 IV（n = 81，有斑块和 COPD）。血清 MMP-1、-7、-10-12 的水平受吸烟影响显著，并且在 COPD 和颈动脉斑块患者中 MMP-1、-3、-7 和-12 水平升高。在调整了传统危险因素后，MMP-1 和-12 仍然具有统计学意义。
即使在调整了危险因素后，COPD 和颈动脉斑块并存与 MMP-1 和 -MMP-12 水平升高相关。需要进一步的研究来阐明这两种 MMP 是否可以作为临床环境中的生物标志物。吸烟与血清 MMP 水平升高（除 MMP-3 外）有关，在解释血清 MMP 结果时应考虑到这一点。
